nabumetone has been researched along with Gastroduodenal Ulcer in 14 studies
Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.
nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.
| Excerpt | Relevance | Reference |
|---|---|---|
| ", Skokie, Illinois) administered twice daily with that of nabumetone 1500 mg administered once daily in 1203 patients with symptomatic osteoarthritis (OA) of the hip or knee." | 9.09 | Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. ( Agrawal, NM; Ball, J; Bocanegra, TS; Caldwell, J; Dhadda, S; Hancock, L; Hurley, S; Kivitz, AJ; Weaver, AL, 1999) |
| "The results suggest that nabumetone was similar in efficacy by most criteria to diclofenac SR and piroxicam in relieving the symptoms of osteoarthritis; however, nabumetone's GI safety profile was generally superior to that of both comparator NSAIDs." | 9.09 | Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety. ( Palmer, RH; Scott, DL, 2000) |
| "To compare the efficacy and safety of nabumetone and diclofenac sodium in the treatment of patients with rheumatoid arthritis (RA)." | 9.09 | [Comparison of the efficacy and safety of nabumetone and diclofenac sodium in the treatment of patients with rheumatoid arthritis]. ( , 2001) |
| " Nabumetone (Relafen), a new NSAID for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), may differ from the others." | 8.78 | Nabumetone: a new NSAID for rheumatoid arthritis and osteoarthritis. ( Roth, SH, 1992) |
| "To identify the unbiased differences in the risk of hospitalization with peptic ulcer disease (PUD) or gastrointestinal (GI) hemorrhage among populations using 4 nonsteroidal antiinflammatory drugs (NSAID): nabumetone, Arthrotec, diclofenac plus a cytoprotective agent dispensed separately (diclo+coRx), and naproxen." | 7.73 | Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study. ( Ashworth, NL; Muhajarine, N; Peloso, PM; Stang, M, 2005) |
| ", Skokie, Illinois) administered twice daily with that of nabumetone 1500 mg administered once daily in 1203 patients with symptomatic osteoarthritis (OA) of the hip or knee." | 5.09 | Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. ( Agrawal, NM; Ball, J; Bocanegra, TS; Caldwell, J; Dhadda, S; Hancock, L; Hurley, S; Kivitz, AJ; Weaver, AL, 1999) |
| "The results suggest that nabumetone was similar in efficacy by most criteria to diclofenac SR and piroxicam in relieving the symptoms of osteoarthritis; however, nabumetone's GI safety profile was generally superior to that of both comparator NSAIDs." | 5.09 | Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety. ( Palmer, RH; Scott, DL, 2000) |
| "To evaluate the efficacy and gastrointestinal safety of nabumetone and diclofenac in the treatment of elderly patients with osteoarthritis, participating in a 3-month efficacy trial." | 5.09 | Treatment of elderly patients with nabumetone or diclofenac: gastrointestinal safety profile. ( DeLapp, R; Kaine, J; Morgan , GJ; Palmer, R, 2001) |
| "To compare the efficacy and safety of nabumetone and diclofenac sodium in the treatment of patients with rheumatoid arthritis (RA)." | 5.09 | [Comparison of the efficacy and safety of nabumetone and diclofenac sodium in the treatment of patients with rheumatoid arthritis]. ( , 2001) |
| "The objective of this endoscopic, double-blind study was to evaluate the gastric tolerability of nabumetone, a novel nonsteroidal anti-inflammatory drug, compared with naproxen in patients with rheumatoid arthritis." | 5.08 | Gastroduodenal tolerability of nabumetone versus naproxen in the treatment of rheumatic patients. ( Bianchi Porro, G; Caruso, I; Imbesi, V; Montrone, F; Petrillo, M, 1995) |
| "To compare the gastrointestinal safety, ulcerogenic potential, and clinical efficacy over 5 years of nabumetone and naproxen therapy, in patients with rheumatoid arthritis (RA) or osteoarthritis (OA)." | 5.07 | A longterm endoscopic evaluation of patients with arthritis treated with nabumetone vs naproxen. ( Bennett, R; Caldron, P; Koepp, R; Mitchell, C; Roth, SH; Swenson, C, 1994) |
| " In an ongoing study of patients with osteo- or rheumatoid arthritis, currently in its fourth year, nabumetone has been shown to be relatively gastric sparing when compared with naproxen." | 5.06 | New understandings of NSAID gastropathy. ( Roth, SH, 1989) |
| "A total of 1,924 persons (rheumatoid arthritis, 835; osteoarthritis, 1,073; volunteers, 16) received nabumetone in United States clinical trials." | 5.06 | Safety evaluation of nabumetone in United States clinical trials. ( Brindley, DA; Jackson, RE; Mitchell, FN, 1987) |
| "Prespecified analysis of all 8 double-blind, randomized phase 2b/3 rofecoxib osteoarthritis trials conducted from December 1996 through March 1998, including one 6-week dose-ranging study, two 6-week efficacy studies vs ibuprofen and placebo, two 1-year efficacy studies vs diclofenac, two 6-month endoscopy studies vs ibuprofen and placebo, and one 6-week efficacy study vs nabumetone and placebo." | 4.80 | Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. ( Bolognese, JA; Harper, SE; Jensen, DM; Langman, MJ; Quan, H; Simon, TJ; Watson, DJ; Zhao, PL, 1999) |
| " Nabumetone (Relafen), a new NSAID for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), may differ from the others." | 4.78 | Nabumetone: a new NSAID for rheumatoid arthritis and osteoarthritis. ( Roth, SH, 1992) |
| "To identify the unbiased differences in the risk of hospitalization with peptic ulcer disease (PUD) or gastrointestinal (GI) hemorrhage among populations using 4 nonsteroidal antiinflammatory drugs (NSAID): nabumetone, Arthrotec, diclofenac plus a cytoprotective agent dispensed separately (diclo+coRx), and naproxen." | 3.73 | Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study. ( Ashworth, NL; Muhajarine, N; Peloso, PM; Stang, M, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (14.29) | 18.7374 |
| 1990's | 8 (57.14) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashworth, NL | 1 |
| Peloso, PM | 1 |
| Muhajarine, N | 1 |
| Stang, M | 1 |
| Bianchi Porro, G | 1 |
| Montrone, F | 1 |
| Petrillo, M | 1 |
| Caruso, I | 1 |
| Imbesi, V | 1 |
| Roth, SH | 5 |
| Bennett, R | 1 |
| Caldron, P | 1 |
| Mitchell, C | 1 |
| Swenson, C | 1 |
| Koepp, R | 1 |
| Tindall, EA | 1 |
| Jain, AK | 1 |
| McMahon, FG | 1 |
| April, PA | 1 |
| Bockow, BI | 1 |
| Cohen, SB | 1 |
| Fleischmann, RM | 1 |
| Lanza, FL | 1 |
| Agrawal, NM | 1 |
| Caldwell, J | 1 |
| Kivitz, AJ | 1 |
| Weaver, AL | 1 |
| Bocanegra, TS | 1 |
| Ball, J | 1 |
| Dhadda, S | 1 |
| Hurley, S | 1 |
| Hancock, L | 1 |
| Langman, MJ | 1 |
| Jensen, DM | 1 |
| Watson, DJ | 1 |
| Harper, SE | 1 |
| Zhao, PL | 1 |
| Quan, H | 1 |
| Bolognese, JA | 1 |
| Simon, TJ | 1 |
| Scott, DL | 1 |
| Palmer, RH | 1 |
| Morgan , GJ | 1 |
| Kaine, J | 1 |
| DeLapp, R | 1 |
| Palmer, R | 1 |
| Jackson, RE | 1 |
| Mitchell, FN | 1 |
| Brindley, DA | 1 |
4 reviews available for nabumetone and Gastroduodenal Ulcer
| Article | Year |
|---|---|
Gastrointestinal toxicity of newer NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Etodolac; Gastrointestinal Hemorrhage; Humans; N | 1993 |
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cyclooxyg | 1999 |
Nabumetone: a new NSAID for rheumatoid arthritis and osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Humans; Nabumetone; Osteo | 1992 |
NSAID gastropathy. The central issue.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Humans; Nabumetone; Naproxen; Peptic Ulcer | 1990 |
9 trials available for nabumetone and Gastroduodenal Ulcer
| Article | Year |
|---|---|
Gastroduodenal tolerability of nabumetone versus naproxen in the treatment of rheumatic patients.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Double-Blind Method; Duod | 1995 |
A longterm endoscopic evaluation of patients with arthritis treated with nabumetone vs naproxen.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Double-Blind Method | 1994 |
A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa.
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Endoscopy, Digestive | 1993 |
Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Diclofenac; Double-Blind Method; Dr | 1999 |
Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Digestive System; Double-Blind Meth | 2000 |
Treatment of elderly patients with nabumetone or diclofenac: gastrointestinal safety profile.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Butanones; D | 2001 |
[Comparison of the efficacy and safety of nabumetone and diclofenac sodium in the treatment of patients with rheumatoid arthritis].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; | 2001 |
New understandings of NSAID gastropathy.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Butanones; Clinical Trials as Topic | 1989 |
Safety evaluation of nabumetone in United States clinical trials.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Clinical Tri | 1987 |
1 other study available for nabumetone and Gastroduodenal Ulcer
| Article | Year |
|---|---|
Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cohort Studies; Databas | 2005 |